Peripheral Arterial Disease Management Guidelines

Evidence-Based Treatment Approaches

• The American College of Cardiology recommends supervised exercise therapy as the most effective initial treatment for intermittent claudication, with programs consisting of 30-45 minutes per session, at least 3 sessions per week, for a minimum of 12 weeks 3
• Cilostazol (100 mg orally twice daily) is a Class I recommendation for improving symptoms and increasing walking distance by 40-60% after 12-24 weeks, though it is contraindicated in patients with heart failure 3
• Antiplatelet therapy with aspirin (75-325 mg daily) or clopidogrel (75 mg daily) is recommended to reduce cardiovascular events in PAD patients 3
• The American College of Cardiology recommends antihypertensive therapy to achieve blood pressure goals of <140/90 mmHg (non-diabetics) or <130/80 mmHg (diabetics and those with chronic kidney disease) 2, 4
• Beta-blockers are effective antihypertensive agents and are not contraindicated in PAD patients 1, 2
• ACE inhibitors are reasonable for symptomatic PAD patients to reduce adverse cardiovascular events, with ramipril shown to reduce risk of MI, stroke, or vascular death by approximately 25% 1, 5
• Statin therapy is indicated for all PAD patients to achieve LDL cholesterol <100 mg/dL, with a target of <70 mg/dL reasonable for very high-risk patients 2, 4
• Diabetes management should aim for hemoglobin A1C <7% to reduce microvascular complications 1, 2
• The American College of Cardiology/American Heart Association does not include calcium channel blockers like nifedipine in their recommendations for PAD management 1, 2, 4